Videos

Data suggests the candidate can reduce the number of injections and treatment burden for patients

In the latest episode of The Retina TL;DR, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Duker about a sustained-release tyrosine kinase inhibitor that could redefine the durability and convenience of anti-VEGF therapy.

The EURETINA meeting featured new treatments in gene therapy and innovative implants to enhance patient quality of life.

A panelist discusses how retina specialists, residents, and fellows manage geographic atrophy by emphasizing early diagnosis, navigating new anticomplement therapies, and improving patient communication to build confidence and personalize treatment in evolving clinical settings.

Dr. Kristina Pfau discusses her research on pseudoxanthoma elasticum and the initiatives of EURETINA's Young Ophthalmologist and Retina Specialists Committee.

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

Daniela Bacherini, MD, PhD, FEBO, said modern imaging modalities open up new possibilities in the peripheral retinal space.

The ultimate goal of redefining endpoints is enabling earlier diagnosis and treatment, said Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

At the EURETINA congress, Prof Pollreisz shared his contemporary approach to multimodal imaging in patients with diabetes.

During the EURETINA session, Stela Vujosevic, MD, PhD, FEBO, posed questions about the current staging for diabetic macular edema and diabetic retinopathy.

At the EURETINA meeting, Professor Uy described the ways artificial intelligence can augment an existing imaging workflow.

The EURETINA YOURS program prepares retina specialists for the EBO exam and helps them find training in the competitive subspecialty of vitreoretinal surgery.

Prof. Querques broke down perifoveal vascular anomalous complex (PVAC) and telangiectatic capillaries (TelCaps) for congress delegates.

Prof. Androudi said differential diagnoses are more important than ever in the era of cell and gene therapies.

During her Ophthalmologica Lecture at the 2025 EURETINA Congress, Prof Cicinelli explained why it's time for a different approach to white spot syndromes.

At the 2025 EURETINA Congress, Prof Korobelnik delivered the Gisbert Richard Lecture, focusing on removal of intra-ocular foreign bodies and mitigating ocular trauma.

María Berrocal, MD, titled her Kreissig Award Lecture "Throwing away wisdom: How we abandon what works."

Aleksandra Rachitskaya, MD, FASRS, is a member of the Modern Retina editorial advisory board.

The International Retinal Imaging Society (IntRIS) had a significant presence at this year's EURETINA Congress.

In her keynote address, Prof Schmidt-Erfurth focused on new artificial intelligence tools and their usage in addressing age-related macular degeneration.